3D Cell Cultures as Prospective Models to Study Extracellular Vesicles in Cancer.

3D culture cancer extracellular vesicles therapy tumoral cells

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
15 Jan 2021
Historique:
received: 17 12 2020
revised: 10 01 2021
accepted: 12 01 2021
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 21 1 2021
Statut: epublish

Résumé

The improvement of culturing techniques to model the environment and physiological conditions surrounding tumors has also been applied to the study of extracellular vesicles (EVs) in cancer research. EVs role is not only limited to cell-to-cell communication in tumor physiology, they are also a promising source of biomarkers, and a tool to deliver drugs and induce antitumoral activity. In the present review, we have addressed the improvements achieved by using 3D culture models to evaluate the role of EVs in tumor progression and the potential applications of EVs in diagnostics and therapeutics. The most employed assays are gel-based spheroids, often utilized to examine the cell invasion rate and angiogenesis markers upon EVs treatment. To study EVs as drug carriers, a more complex multicellular cultures and organoids from cancer stem cell populations have been developed. Such strategies provide a closer response to in vivo physiology observed responses. They are also the best models to understand the complex interactions between different populations of cells and the extracellular matrix, in which tumor-derived EVs modify epithelial or mesenchymal cells to become protumor agents. Finally, the growth of cells in 3D bioreactor-like systems is appointed as the best approach to industrial EVs production, a necessary step toward clinical translation of EVs-based therapy.

Identifiants

pubmed: 33467651
pii: cancers13020307
doi: 10.3390/cancers13020307
pmc: PMC7830667
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Spanish ministry of Science and Innovation
ID : RTI2018-094969-B-I00
Organisme : Severo Ochoa Excellence Grant
ID : SEV-2016-0644
Organisme : Horizon 2020 Framework Programme
ID : 860303

Références

Prostate. 2019 Nov;79(15):1767-1776
pubmed: 31475741
Sci Rep. 2019 Sep 10;9(1):13012
pubmed: 31506601
Oncotarget. 2016 Aug 2;7(31):50086-50098
pubmed: 27418137
Acta Biomater. 2017 Jan 1;47:1-13
pubmed: 27721010
J Control Release. 2012 Dec 10;164(2):192-204
pubmed: 22613880
Cancers (Basel). 2020 May 16;12(5):
pubmed: 32429403
Methods Mol Biol. 2011;695:1-15
pubmed: 21042962
Mol Cell Proteomics. 2013 Mar;12(3):587-98
pubmed: 23230278
Arch Med Sci. 2018 Jun;14(4):910-919
pubmed: 30002710
J Cell Physiol. 2015 Jan;230(1):16-26
pubmed: 24912145
Mol Oncol. 2014 Mar;8(2):351-65
pubmed: 24388494
Cancer Res. 2019 Apr 1;79(7):1681-1695
pubmed: 30674533
Biomaterials. 2014 Mar;35(10):3319-30
pubmed: 24447463
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842290
Lab Chip. 2020 Feb 7;20(3):548-557
pubmed: 31942592
Theranostics. 2017 Mar 16;7(5):1333-1345
pubmed: 28435469
Crit Rev Clin Lab Sci. 2016;53(2):121-31
pubmed: 26479834
Carcinogenesis. 2018 Dec 13;39(11):1368-1379
pubmed: 30184100
Int J Nanomedicine. 2020 Nov 24;15:9355-9371
pubmed: 33262592
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158314
Biomaterials. 2014 Jun;35(18):4940-9
pubmed: 24661550
Front Oncol. 2018 Oct 10;8:376
pubmed: 30364132
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):
pubmed: 29158312
Curr Opin Neurobiol. 2012 Oct;22(5):768-77
pubmed: 22405989
Oncotarget. 2015 Feb 10;6(4):2046-63
pubmed: 25514462
Acta Biomater. 2018 Aug;76:146-153
pubmed: 30078422
Cancer Sci. 2018 Aug;109(8):2364-2374
pubmed: 29908100
Chem Soc Rev. 2009 Apr;38(4):1139-51
pubmed: 19421585
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Front Cell Dev Biol. 2020 Mar 18;8:166
pubmed: 32258040
Anal Chem. 2011 Nov 15;83(22):8454-9
pubmed: 21985643
Life Sci Alliance. 2019 Jun 3;2(3):
pubmed: 31160380
Cell Mol Life Sci. 2019 Jun;76(12):2463-2476
pubmed: 31028424
Front Cell Dev Biol. 2018 Feb 20;6:18
pubmed: 29515996
PLoS One. 2018 Feb 7;13(2):e0191109
pubmed: 29415026
Int J Oncol. 2018 May;52(5):1651-1660
pubmed: 29568945
Oncol Lett. 2017 Dec;14(6):6999-7010
pubmed: 29344128
J Immunol. 2003 Sep 1;171(5):2517-23
pubmed: 12928401
Int J Cancer. 2012 May 1;130(9):2033-43
pubmed: 21630268
Adv Biosyst. 2020 Dec;4(12):e1900305
pubmed: 32394646
Nat Biotechnol. 2011 Apr;29(4):341-5
pubmed: 21423189
Biomaterials. 2013 Oct;34(30):7408-17
pubmed: 23827186
Endocr Relat Cancer. 2020 May;27(5):R133-R144
pubmed: 32203935
Biomaterials. 2017 Apr;124:12-24
pubmed: 28182873
Cells. 2020 Sep 04;9(9):
pubmed: 32899718
Hum Mol Genet. 2015 Jul 1;24(13):3689-98
pubmed: 25832648
Mol Med Rep. 2013 Jul;8(1):272-6
pubmed: 23652371
Acta Biomater. 2019 Sep 1;95:236-244
pubmed: 30471476
Nat Commun. 2019 Aug 23;10(1):3838
pubmed: 31444335
Tissue Eng Part B Rev. 2010 Jun;16(3):351-9
pubmed: 20092396
PLoS One. 2018 Sep 27;13(9):e0204276
pubmed: 30260987
NPJ Precis Oncol. 2020 Jul 27;4:18
pubmed: 32793806
Dose Response. 2019 Dec 9;17(4):1559325819891004
pubmed: 31839757
Int J Cancer. 2019 Jun 15;144(12):3070-3085
pubmed: 30556600
Oncol Rep. 2016 Nov;36(5):3065-3071
pubmed: 27666412
Adv Drug Deliv Rev. 2014 Apr;69-70:42-51
pubmed: 24412474
Biomaterials. 2012 Mar;33(9):2673-80
pubmed: 22240510
Anticancer Res. 2018 Sep;38(9):5139-5147
pubmed: 30194161
Oncotarget. 2015 Jan 20;6(2):715-31
pubmed: 25596732
Front Cell Dev Biol. 2020 Sep 17;8:553576
pubmed: 33042993
Biochem Biophys Res Commun. 2020 Apr 9;524(3):649-655
pubmed: 32033746
J Cell Sci. 2002 Jun 15;115(Pt 12):2505-15
pubmed: 12045221
Acta Biomater. 2017 Aug;58:26-33
pubmed: 28532902
Nanoscale. 2018 May 10;10(18):8547-8559
pubmed: 29693684
Int J Oncol. 2019 May;54(5):1567-1578
pubmed: 30896790
World J Gastroenterol. 2015 May 28;21(20):6215-28
pubmed: 26034356
Am J Physiol Cell Physiol. 2020 Jul 1;319(1):C151-C165
pubmed: 32459504
Int J Mol Sci. 2019 Oct 09;20(20):
pubmed: 31600881
Assay Drug Dev Technol. 2016 Jan-Feb;14(1):19-28
pubmed: 26866750
Biomaterials. 2019 Apr;198:167-179
pubmed: 29807624
Semin Cancer Biol. 2005 Oct;15(5):378-86
pubmed: 15975825
Chemphyschem. 2018 May 22;19(10):1205-1214
pubmed: 29327816
Methods. 2020 May 1;177:58-66
pubmed: 32061674
Angiogenesis. 2012 Mar;15(1):33-45
pubmed: 22203239
Semin Cancer Biol. 2005 Oct;15(5):405-12
pubmed: 16055341
Methods Mol Biol. 2011;695:17-39
pubmed: 21042963
J R Soc Interface. 2012 Nov 7;9(76):2883-98
pubmed: 22683525
Biochem Biophys Rep. 2020 Aug 04;23:100792
pubmed: 32793818
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
Proteomics. 2020 Jul;20(14):e2000016
pubmed: 32438511
Proteomics. 2014 Mar;14(4-5):412-25
pubmed: 24339442
Theranostics. 2020 Jan 16;10(5):2309-2326
pubmed: 32089744
Biosensors (Basel). 2015 Dec 14;5(4):768-90
pubmed: 26694477
JCI Insight. 2020 Nov 5;5(21):
pubmed: 32990680
Nat Cell Biol. 2015 Feb;17(2):183-94
pubmed: 25621950
Biomaterials. 2014 Feb;35(7):2383-90
pubmed: 24345736
Cancer Sci. 2020 Jan;111(1):98-111
pubmed: 31715081
Gastroenterology. 2019 Feb;156(3):722-734.e6
pubmed: 30342032
Oncotarget. 2018 May 15;9(37):24766-24777
pubmed: 29872504
Pharmaceutics. 2019 Oct 28;11(11):
pubmed: 31661862
Nucleic Acids Res. 2020 Sep 18;48(16):8870-8882
pubmed: 32810272
Theranostics. 2019 Oct 17;9(26):8001-8017
pubmed: 31754377
Cell Stem Cell. 2016 Jun 2;18(6):827-838
pubmed: 27212702
Drug Deliv. 2018 Nov;25(1):1790-1801
pubmed: 30785308
Int J Cancer. 2019 Oct 15;145(8):2209-2224
pubmed: 30980673
Biotechnol Bioeng. 2020 Oct 21;:
pubmed: 33085083
J Hematol Oncol. 2019 Jan 25;12(1):10
pubmed: 30683126
Cell. 2018 Dec 13;175(7):1972-1988.e16
pubmed: 30550791
BMC Cancer. 2018 Nov 5;18(1):1065
pubmed: 30396333
Nat Med. 2017 Dec;23(12):1424-1435
pubmed: 29131160
Lab Chip. 2019 May 14;19(10):1877-1886
pubmed: 31044204
J Clin Invest. 2016 Apr 1;126(4):1163-72
pubmed: 26974161
Oncotarget. 2016 Aug 30;7(35):56904-56914
pubmed: 27486877
ACS Appl Mater Interfaces. 2018 Apr 18;10(15):12341-12350
pubmed: 29564886
J Enzyme Inhib Med Chem. 2017 Dec;32(1):648-657
pubmed: 28262028
Curr Opin Cell Biol. 2002 Oct;14(5):633-9
pubmed: 12231360
Front Cell Dev Biol. 2020 Jul 07;8:558
pubmed: 32775326
Nat Rev Cancer. 2014 Jun;14(6):430-9
pubmed: 24827502

Auteurs

Guillermo Bordanaba-Florit (G)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Exosomes Laboratory, Basque Research and Technology Alliance (BRTA), E48160 Derio, Spain.

Iratxe Madarieta (I)

TECNALIA Basque Research and Technology Alliance (BRTA), E20009 Donostia San Sebastian, Spain.

Beatriz Olalde (B)

TECNALIA Basque Research and Technology Alliance (BRTA), E20009 Donostia San Sebastian, Spain.

Juan M Falcón-Pérez (JM)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Exosomes Laboratory, Basque Research and Technology Alliance (BRTA), E48160 Derio, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), E28029 Madrid, Spain.
Ikerbasque, Basque Foundation for Science, E48009 Bilbao, Spain.

Félix Royo (F)

Center for Cooperative Research in Biosciences (CIC bioGUNE), Exosomes Laboratory, Basque Research and Technology Alliance (BRTA), E48160 Derio, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), E28029 Madrid, Spain.

Classifications MeSH